Fact Sheet | What You Need to Know: Medicare to Begin Limited Coverage of GLP-1 Medications

May 2026

Medicare will begin limited coverage of GLP-1s for certain
beneficiaries beginning July 1, 2026.

Investing in Health Equity | Why New Jersey Should Cover FDA-Approved Medications Through Medicaid

March 2026

New Jersey is at a critical inflection point. Like many states, obesity is on the rise in New Jersey, increasing by roughly 6% over the past decade. Without action, these rates could skyrocket, furthering a health equity crisis, and posing a threat to the state’s Medicaid program, public health infrastructure, and long-term economic stability.

Investing in Health Equity | Why New York Should Cover FDA-Approved Anti-Obesity Medications Through Medicaid

March 2026

New York faces an urgent challenge: without early, evidence-based intervention, today’s obesity crisis will become tomorrow’s diabetes, cardiovascular disease, or disability crisis all leading to ballooned Medicaid expenditures.

Protect Maryland’s Future | Why Maryland’s
Medical Assistance Program Should Cover
FDA-Approved Anti-Obesity Medications

February 2026

Expanding Maryland Medicaid to ensure
access to comprehensive,
evidence-based obesity treatments would
improve health outcomes, strengthen
health equity, and help reduce long-term
healthcare costs.

Investing in Health Equity | Why New Mexico Should Cover FDA-Approved Anti-Obesity Medications Through Medicaid

February 2026

New Mexico has an opportunity to take decisive action to support Medicaid coverage of FDA-approved AOMs.

Comprehensive Care Necessary to Successfully Treat Disease of Obesity

September 2024

Healthy eating is associated with lower rates of obesity. However, people experiencing poverty struggle to regularly afford critical healthy food items such as proteins, raw fruits, and vegetables.